

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse HVEM/TNFRSF14 in direct ELISAs.
Source	Monoclonal Rabbit IgG Clone # 2024B
Purification	Protein A or G purified from cell culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse HVEM/TNFRSF14 Gln39-Val207 Accession # NP_849262
Conjugate	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.

*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	Mouse splenocytes and CHO Chinese hamster ovary cell line transfected with mouse HVEM

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. ● 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

HVEM (herpesvirus entry mediator) is a type I membrane protein that is TNF receptor superfamily member 14 (TNFRSF14) (1). The mouse HVEM cDNA encodes a 275 amino acid (aa) protein. It contains a 36 aa signal peptide, a 170 aa extracellular domain with three cysteine rich domains (CRD), a 24 aa transmembrane region and a 45 aa cytoplasmic tail with a TRAF interaction domain (1). HVEM expression is highest on naïve, memory and regulatory T cells, but declines during T cell activation (2, 3). It is present at low levels on most resting leukocytes (4). HVEM is a receptor for the IGSF member BTLA (B and T lymphocyte attenuator), CD160, and the TNF family ligand LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes) (2, 9). HVEM and BT LA are constitutively expressed on T cells, while LIGHT is generally considered to be inducible upon TCR activation. In the absence of activation, HVEM and BT LA interact monomerically, either in cis, or in trans. A same cell (or cis) interaction likely promotes general cell survival, while a between cell (or trans) interaction promotes a state of lymphocyte inactivity through the BT LA cytoplasmic domain. Following T cell activation, LIGHT appears and disrupts existing HVEM-BT LA bonds. A LIGHT-HVEM trimer now forms in trans, initiating HVEM-mediated NFκB signaling and a proinflammatory response (10). BT LA and LIGHT interactions are not mutually exclusive, but BT LA appears dominant (4, 6, 7). The herpesvirus envelope glycoprotein gD, which binds HVEM CRD1 to initiate membrane fusion, can antagonize both BT LA and LIGHT binding (1, 6, 7, 9). Human, but not mouse, HVEM can also bind lymphotoxin α within CRD2 3 (9, 11). Graft-v s-host disease and Th1 type intestinal inflammation can be ameliorated by interrupting T cell LIGHT/HVEM interactions, while disruption of BT LA/HVEM interaction promotes intestinal inflammation (12-14). Mouse HVEM ECD shares 89% and 53% aa identity with rat and human HVEM, respectively. Mouse HVEM can recognize human BT LA and LIGHT, but human HVEM does not recognize mouse ligands (2, 11).

References:

1. Hsu, H. et al. (1997) J. Biol. Chem. **272**:13471.
2. Sedy, J.R. et al. (2005) Nat. Immunol. **6**:90.
3. Tao, R. et al. (2008) J. Immunol. **180**:6649.
4. Wang, Y. et al. (2005) J. Clin. Invest. **115**:711.
5. Nelson, C.A. et al. (2008) J. Immunol. **180**:940.
6. Gonzales, L.C. et al. (2005) Proc. Natl. Acad. Sci. USA **102**:1116.
7. Compaan, D.M. et al. (2005) J. Biol. Chem. **280**:39553.
8. Cai, G. et al. (2008) Nat. Immunol. **9**:176.
9. Mauri, D.N. et al. (1998) Immunity **8**:21.
10. Ware, C.F. (2008) Immunol. Rev. **223**:186.
11. Bossen, C. et al. (2006) J. Biol. Chem. **281**:13964.
12. Xu, Y. et al. (2007) Blood **109**:4097.
13. Wang, J. et al. (2005) J. Immunol. **174**:8173.
14. Steinberg, M.W. et al. (2008) J. Exp. Med. **205**:1463.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.